» Articles » PMID: 19818098

Zoledronic Acid Repolarizes Tumour-associated Macrophages and Inhibits Mammary Carcinogenesis by Targeting the Mevalonate Pathway

Abstract

It is unknown whether zoledronic acid (ZA) at clinically relevant doses is active against tumours not located in bone. Mice transgenic for the activated ErbB-2 oncogene were treated with a cumulative number of doses equivalent to that recommended in human beings. A significant increase in tumour-free and overall survival was observed in mice treated with ZA. At clinically compatible concentrations, ZA modulated the mevalonate pathway and affected protein prenylation in both tumour cells and macrophages. A marked reduction in the number of tumour-associated macrophages was paralleled by a significant decrease in tumour vascularization. The local production of vascular endothelial growth factor and interleukin-10 was drastically down-regulated in favour of interferon-γ production. Peritoneal macrophages and tumour-associated macrophages of ZA-treated mice recovered a full M1 antitumoral phenotype, as shown by nuclear translocation of nuclear factor kB, inducible nitric oxide synthase expression and nitric oxide production. These data indicate that clinically achievable doses of ZA inhibit spontaneous mammary cancerogenesis by targeting the local microenvironment, as shown by a decreased tumour vascularization, a reduced number of tumour-associated macrophages and their reverted polarization from M2 to M1 phenotype.

Citing Articles

Interactions between tumor-associated macrophages and regulated cell death: therapeutic implications in immuno-oncology.

Ge Y, Jiang L, Yang C, Dong Q, Tang C, Xu Y Front Oncol. 2024; 14:1449696.

PMID: 39575419 PMC: 11578871. DOI: 10.3389/fonc.2024.1449696.


Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics.

Muteeb G, Khafaga D, El-Morsy M, Farhan M, Aatif M, Hosney M Heliyon. 2024; 10(18):e37217.

PMID: 39309874 PMC: 11415663. DOI: 10.1016/j.heliyon.2024.e37217.


The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets.

Lorestani P, Dashti M, Nejati N, Habibi M, Askari M, Robat-Jazi B Discov Oncol. 2024; 15(1):369.

PMID: 39186144 PMC: 11347554. DOI: 10.1007/s12672-024-01256-x.


Immune mediated support of metastasis: Implication for bone invasion.

Xin Z, Qin L, Tang Y, Guo S, Li F, Fang Y Cancer Commun (Lond). 2024; 44(9):967-991.

PMID: 39003618 PMC: 11492328. DOI: 10.1002/cac2.12584.


Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma.

Li D, Zhang T, Guo Y, Bi C, Liu M, Wang G Cell Death Dis. 2024; 15(7):498.

PMID: 38997297 PMC: 11245522. DOI: 10.1038/s41419-024-06888-z.


References
1.
Heijnen H, van Donselaar E, Slot J, Fries D, Blachard-Fillion B, Hodara R . Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase. Free Radic Biol Med. 2006; 40(11):1903-13. DOI: 10.1016/j.freeradbiomed.2005.09.006. View

2.
Winter M, Holen I, Coleman R . Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008; 34(5):453-75. DOI: 10.1016/j.ctrv.2008.02.004. View

3.
Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y . The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood. 2003; 102(6):2229-35. DOI: 10.1182/blood-2003-01-0305. View

4.
Aktan F . iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004; 75(6):639-53. DOI: 10.1016/j.lfs.2003.10.042. View

5.
Fiore F, Castella B, Nuschak B, Bertieri R, Mariani S, Bruno B . Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood. 2007; 110(3):921-7. DOI: 10.1182/blood-2006-09-044321. View